

BioScrip, Inc.  
Form 8-K  
June 22, 2016

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): June 22, 2016

**BIOSCRIP, INC.**

(Exact name of Registrant as specified in its charter)

Delaware	000-28740	05-0489664
(State of Incorporation)	(Commission File Number)	(I.R.S. Employer
		Identification No.)

1600 Broadway, Suite 950, Denver, Colorado	80202
(Address of principal executive offices)	(Zip Code)

Registrant's telephone number, including area code: (720) 697-5200

N/A

Edgar Filing: BioScrip, Inc. - Form 8-K

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01 – Other Events.**

On June 22, 2016, the Company issued a press release announcing the completion of its previously announced underwritten public offering of 45,200,000 shares of its common stock, including 5,200,000 shares of common stock issued upon full exercise of the underwriters' over-allotment option, at a public offering price of \$2.00 per share. The offering resulted in net proceeds of approximately \$83.15 million, after deducting underwriting discounts and commissions and offering expenses. A copy of the press release is furnished as Exhibit 99.1 to this report.

**Item 9.01 – Financial Statements and Exhibits.**

(d) Exhibits

**Exhibit Number Description**

99.1	Press Release dated June 22, 2016.
------	------------------------------------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**BIOSCRIP, INC.**

Date: June 22, 2016 /s/ Kathryn M. Stalmack

By: Kathryn M. Stalmack

Senior Vice President, General Counsel and Secretary

**Index to Exhibits**

**Exhibit Number Description**

99.1	Press Release dated June 22, 2016.
------	------------------------------------